Emicizumab mode of action

Emicizumab is a monoclonal antibody medication used to treat individuals with Hemophilia A, a genetic disorder that impairs the body's ability to form blood clots and stop bleeding. Hemophilia A is caused by a deficiency or dysfunction of a clotting protein called Factor VIII. Emicizumab is a bispecific antibody that mimics the function of Factor VIII and Factor IX, which are clotting proteins that work together to stop bleeding.